Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
February 02, 2023 08:30 ET
|
Unicycive Therapeutics, Inc.
Develops Renazorb opportunity in new market for patients with hyperphosphatemia Agreement includes upfront payment, royalties, and milestone payments LOS ALTOS, Calif., Feb. 02, 2023 (GLOBE...
Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings
January 23, 2023 07:00 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023
January 05, 2023 07:00 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
December 29, 2022 11:31 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
December 28, 2022 08:30 ET
|
Unicycive Therapeutics, Inc.
Renazorb demonstrates pharmacodynamic bioequivalence to Fosrenol Renazorb’s enhanced product profile features reduced pill burden and small, swallowable tablets, which may improve patient compliance...
Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
December 22, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease,...
Unicycive to Participate in Upcoming Investor Conferences
November 28, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs,...
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy
November 21, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
Treatment with UNI-494 improved contrast vision in animal models of geographic atrophy (GA) GA is an advanced form of Age-related Macular Degeneration (AMD) and there are currently no FDA-approved...
Unicycive Announces Third Quarter Financial Results and Provides Business Update
November 14, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
Topline results by year-end as enrollment completed for pivotal bioequivalence study of RENAZORB™ (lanthanum dioxycarbonate), an investigational phosphate binder for the treatment of hyperphosphatemia...
Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis
November 10, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
Topline Data Expected by Year End 2022 On Track to File the NDA in 2023 LOS ALTOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage...